Other languages Chimerix, Inc.

Equities

CMRX

US16934W1062

Delayed Nasdaq Other stock markets 01:37:51 2024-04-29 pm EDT			5-day change	1st Jan Change
0.9063 ^USD	+0.71%		-0.83%	-5.84%

Mar. 21	Chimerix Appoints Marc D. Kozin to Board of Directors	CI
Feb. 29	Transcript : Chimerix, Inc., Q4 2023 Earnings Call, Feb 29, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chimerix Appoints Marc D. Kozin to Board of Directors	Mar. 21
Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
Chimerix Announces Board Changes	Dec. 29
Chimerix Names Michelle LaSpaluto Finance Chief	Dec. 04
Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer	Nov. 16
Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery	23-08-16
Chimerix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Chimerix, Inc. Announces CEO Changes, Effective on August 1, 2023	23-06-27
Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023	23-06-27
Chimerix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02
Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-02
Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study	22-12-08
Chimerix Responds to Rubric Capital Management	22-11-11
Chimerix Rejects Shareholder Rubric Capital Management's Call for Liquidation	22-11-11
Rubric Capital Management Sends Letter to Chimerix	22-11-10
Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03
Emergent BioSolutions Inc. completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. for approximately $370 million.	22-09-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Chimerix, Inc.

Equities

CMRX

US16934W1062

Other languages

Filters